Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 184

1.

Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients.

Speiser DE, Schwarz K, Baumgaertner P, Manolova V, Devevre E, Sterry W, Walden P, Zippelius A, Conzett KB, Senti G, Voelter V, Cerottini JP, Guggisberg D, Willers J, Geldhof C, Romero P, Kündig T, Knuth A, Dummer R, Trefzer U, Bachmann MF.

J Immunother. 2010 Oct;33(8):848-58. doi: 10.1097/CJI.0b013e3181f1d614.

PMID:
20842051
2.

Vaccination of melanoma patients with Melan-A/Mart-1 peptide and Klebsiella outer membrane protein p40 as an adjuvant.

Lienard D, Avril MF, Le Gal FA, Baumgaertner P, Vermeulen W, Blom A, Geldhof C, Rimoldi D, Pagliusi S, Romero P, Dietrich PY, Corvaia N, Speiser DE.

J Immunother. 2009 Oct;32(8):875-83. doi: 10.1097/CJI.0b013e3181b56ad9.

PMID:
19752746
3.

gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells.

Walker EB, Haley D, Miller W, Floyd K, Wisner KP, Sanjuan N, Maecker H, Romero P, Hu HM, Alvord WG, Smith JW 2nd, Fox BA, Urba WJ.

Clin Cancer Res. 2004 Jan 15;10(2):668-80.

4.

Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.

Palucka AK, Ueno H, Connolly J, Kerneis-Norvell F, Blanck JP, Johnston DA, Fay J, Banchereau J.

J Immunother. 2006 Sep-Oct;29(5):545-57.

PMID:
16971810
5.

Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.

Speiser DE, Liénard D, Rufer N, Rubio-Godoy V, Rimoldi D, Lejeune F, Krieg AM, Cerottini JC, Romero P.

J Clin Invest. 2005 Mar;115(3):739-46.

6.

Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors.

Di Pucchio T, Pilla L, Capone I, Ferrantini M, Montefiore E, Urbani F, Patuzzo R, Pennacchioli E, Santinami M, Cova A, Sovena G, Arienti F, Lombardo C, Lombardi A, Caporaso P, D'Atri S, Marchetti P, Bonmassar E, Parmiani G, Belardelli F, Rivoltini L.

Cancer Res. 2006 May 1;66(9):4943-51.

7.

HLA anchor optimization of the melan-A-HLA-A2 epitope within a long peptide is required for efficient cross-priming of human tumor-reactive T cells.

Chauvin JM, Larrieu P, Sarrabayrouse G, Prévost-Blondel A, Lengagne R, Desfrançois J, Labarrière N, Jotereau F.

J Immunol. 2012 Mar 1;188(5):2102-10. doi: 10.4049/jimmunol.1101807. Epub 2012 Jan 30.

8.

Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine.

Dangoor A, Lorigan P, Keilholz U, Schadendorf D, Harris A, Ottensmeier C, Smyth J, Hoffmann K, Anderson R, Cripps M, Schneider J, Hawkins R.

Cancer Immunol Immunother. 2010 Jun;59(6):863-73. doi: 10.1007/s00262-009-0811-7. Epub 2009 Dec 31.

PMID:
20043222
9.

Human tumor-derived heat shock protein 96 mediates in vitro activation and in vivo expansion of melanoma- and colon carcinoma-specific T cells.

Rivoltini L, Castelli C, Carrabba M, Mazzaferro V, Pilla L, Huber V, Coppa J, Gallino G, Scheibenbogen C, Squarcina P, Cova A, Camerini R, Lewis JJ, Srivastava PK, Parmiani G.

J Immunol. 2003 Oct 1;171(7):3467-74.

10.

In vivo activation of melanoma-specific CD8(+) T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells.

Speiser DE, Liénard D, Pittet MJ, Batard P, Rimoldi D, Guillaume P, Cerottini JC, Romero P.

Eur J Immunol. 2002 Mar;32(3):731-41.

11.

CpG-A oligonucleotides induce a monocyte-derived dendritic cell-like phenotype that preferentially activates CD8 T cells.

Krug A, Rothenfusser S, Selinger S, Bock C, Kerkmann M, Battiany J, Sarris A, Giese T, Speiser D, Endres S, Hartmann G.

J Immunol. 2003 Apr 1;170(7):3468-77.

12.

Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8⁺ T-cell responses in melanoma patients.

Goldinger SM, Dummer R, Baumgaertner P, Mihic-Probst D, Schwarz K, Hammann-Haenni A, Willers J, Geldhof C, Prior JO, Kündig TM, Michielin O, Bachmann MF, Speiser DE.

Eur J Immunol. 2012 Nov;42(11):3049-61. doi: 10.1002/eji.201142361. Epub 2012 Aug 28. Erratum in: Eur J Immunol. 2016 Feb;46(2):493. Eur J Immunol. 2016 Feb;46(2):493.

13.

Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1-binding melanoma and viral peptide antigens.

Herr W, Schneider J, Lohse AW, Meyer zum Büschenfelde KH, Wölfel T.

J Immunol Methods. 1996 May 27;191(2):131-42.

PMID:
8666832
14.

Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA.

Liénard D, Rimoldi D, Marchand M, Dietrich PY, van Baren N, Geldhof C, Batard P, Guillaume P, Ayyoub M, Pittet MJ, Zippelius A, Fleischhauer K, Lejeune F, Cerottini JC, Romero P, Speiser DE.

Cancer Immun. 2004 May 19;4:4.

15.

Ex vivo IFN-gamma secretion by circulating CD8 T lymphocytes: implications of a novel approach for T cell monitoring in infectious and malignant diseases.

Pittet MJ, Zippelius A, Speiser DE, Assenmacher M, Guillaume P, Valmori D, Liénard D, Lejeune F, Cerottini JC, Romero P.

J Immunol. 2001 Jun 15;166(12):7634-40.

16.

Simultaneous coexpression of memory-related and effector-related genes by individual human CD8 T cells depends on antigen specificity and differentiation.

Gupta B, Iancu EM, Gannon PO, Wieckowski S, Baitsch L, Speiser DE, Rufer N.

J Immunother. 2012 Jul;35(6):488-501. doi: 10.1097/CJI.0b013e31826183a7.

PMID:
22735807
17.

Efficient induction of tumor antigen-specific CD8+ memory T cells by recombinant lentivectors.

Chapatte L, Colombetti S, Cerottini JC, Lévy F.

Cancer Res. 2006 Jan 15;66(2):1155-60.

19.

Suboptimal activation of CD8(+) T cells by melanoma-derived altered peptide ligands: role of Melan-A/MART-1 optimized analogues.

Carrabba MG, Castelli C, Maeurer MJ, Squarcina P, Cova A, Pilla L, Renkvist N, Parmiani G, Rivoltini L.

Cancer Res. 2003 Apr 1;63(7):1560-7.

20.

Decreased specific CD8+ T cell cross-reactivity of antigen recognition following vaccination with Melan-A peptide.

Appay V, Speiser DE, Rufer N, Reynard S, Barbey C, Cerottini JC, Leyvraz S, Pinilla C, Romero P.

Eur J Immunol. 2006 Jul;36(7):1805-14.

Supplemental Content

Support Center